行情

PDLI

PDLI

PDL BioPharma
NASDAQ

实时行情|Nasdaq Last Sale

2.160
+0.010
+0.47%
盘后: 2.160 0 0.00% 16:45 09/20 EDT
开盘
2.150
昨收
2.150
最高
2.230
最低
2.150
成交量
835.51万
成交额
--
52周最高
3.890
52周最低
2.150
市值
2.47亿
市盈率(TTM)
7.01
分时
5日
1月
3月
1年
5年

分析师评级

1位分析师的综合评级

中性

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

EPS

PDLI 新闻

  • The Daily Biotech Pulse: FDA Approves Merck HIV Drugs, Five Prime CEO Quits, HTG Molecular Announces Secondary Offering
  • Benzinga.2天前
  • 56 Biggest Movers From Friday
  • Benzinga.6天前
  • Stocks That Hit 52-Week Lows On Friday
  • Benzinga.09/13 19:08
  • PDL Bio extends due date of convertible debt with exchange transaction
  • seekingalpha.09/13 17:54

更多

所属板块

生物技术和医学研究
+0.62%
制药与医学研究
+0.95%

热门股票

名称
价格
涨跌幅

PDLI 简况

PDL BioPharma, Inc. seeks to provide return for its shareholders by acquiring and managing a portfolio of companies, products, royalty agreements and debt facilities in the biotechnology, pharmaceutical and medical device industries. The Company's segments include income generating assets and product sales. The income generating assets segment consists of royalties from issued patents in the United States and elsewhere, covering the humanization of antibodies, which it refers to as the Queen et al. patents; notes and other long-term receivables, royalty rights-at fair value and equity investments. The Company's product sales segment consists of revenue derived from Tekturna, Tekturna HCT, Rasilez and Rasilez HCT (collectively, the Noden Products or Tekturna) sales. It is focused on the acquisition of additional products. As of December 31, 2016, it had a total of five notes receivable transactions outstanding and one note/royalty (hybrid) receivable transaction outstanding.
展开

Webull提供PDL BioPharma Inc的股票价格,实时市场报价,专业分析师评级,深度图表和免费的股票新闻,以帮助您做出投资决策。